Avior Wealth Management LLC Has $600,000 Position in Option Care Health, Inc. (NASDAQ:OPCH)

Avior Wealth Management LLC lifted its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 13.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,814 shares of the company’s stock after buying an additional 2,108 shares during the period. Avior Wealth Management LLC’s holdings in Option Care Health were worth $600,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in OPCH. Morgan Stanley increased its holdings in Option Care Health by 231.1% in the 3rd quarter. Morgan Stanley now owns 3,088,127 shares of the company’s stock valued at $99,901,000 after buying an additional 2,155,316 shares during the period. Vanguard Group Inc. increased its stake in Option Care Health by 11.8% in the third quarter. Vanguard Group Inc. now owns 19,319,352 shares of the company’s stock valued at $624,981,000 after acquiring an additional 2,037,162 shares during the period. Third Point LLC increased its stake in Option Care Health by 55.7% in the third quarter. Third Point LLC now owns 5,450,659 shares of the company’s stock valued at $176,329,000 after acquiring an additional 1,950,659 shares during the period. Norges Bank acquired a new position in Option Care Health in the fourth quarter worth about $51,009,000. Finally, BlackRock Inc. lifted its stake in Option Care Health by 8.5% during the first quarter. BlackRock Inc. now owns 21,444,169 shares of the company’s stock worth $681,281,000 after purchasing an additional 1,671,783 shares during the period. 98.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. bought 35,000 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were bought at an average price of $31.55 per share, for a total transaction of $1,104,250.00. Following the completion of the acquisition, the director now owns 269,528 shares of the company’s stock, valued at $8,503,608.40. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.64% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Jefferies Financial Group upped their price objective on Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Barrington Research upped their price target on Option Care Health from $35.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, February 23rd.

Option Care Health Trading Up 2.1 %

Shares of OPCH stock opened at $30.90 on Friday. The company has a market capitalization of $5.37 billion, a P/E ratio of 21.02, a P/E/G ratio of 1.72 and a beta of 1.22. Option Care Health, Inc. has a 12-month low of $24.23 and a 12-month high of $35.74. The company has a quick ratio of 1.33, a current ratio of 1.77 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average price of $32.31 and a 200 day moving average price of $31.58.

Option Care Health (NASDAQ:OPCH) last posted its earnings results on Thursday, February 22nd. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.03. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Option Care Health had a net margin of 6.21% and a return on equity of 18.78%. Option Care Health’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 earnings per share. Research analysts forecast that Option Care Health, Inc. will post 1.13 earnings per share for the current fiscal year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.